HighTower Advisors LLC Sells 168 Shares of VanEck Biotech ETF (NASDAQ:BBH)

HighTower Advisors LLC trimmed its holdings in shares of VanEck Biotech ETF (NASDAQ:BBH) by 1.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,845 shares of the company’s stock after selling 168 shares during the period. HighTower Advisors LLC owned 0.35% of VanEck Biotech ETF worth $1,569,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Truist Financial Corp raised its position in shares of VanEck Biotech ETF by 3.8% during the 2nd quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock valued at $455,000 after acquiring an additional 100 shares during the last quarter. Hyman Charles D acquired a new stake in shares of VanEck Biotech ETF during the second quarter worth $202,000. Northwestern Mutual Wealth Management Co. increased its holdings in VanEck Biotech ETF by 5.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 24,324 shares of the company’s stock valued at $4,096,000 after purchasing an additional 1,334 shares during the last quarter. Atlas Capital Advisors LLC bought a new stake in VanEck Biotech ETF in the second quarter valued at about $960,000. Finally, International Assets Investment Management LLC lifted its stake in VanEck Biotech ETF by 10,376,390.9% in the third quarter. International Assets Investment Management LLC now owns 1,141,414 shares of the company’s stock valued at $202,475,000 after buying an additional 1,141,403 shares during the period. 32.05% of the stock is currently owned by institutional investors and hedge funds.

VanEck Biotech ETF Stock Performance

VanEck Biotech ETF stock opened at $163.42 on Monday. The business has a 50-day moving average of $169.63 and a 200-day moving average of $173.07. VanEck Biotech ETF has a 1 year low of $151.35 and a 1 year high of $183.64.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.